Pooled analysis of three phase 1 and 2 clinical trials published online ahead of print in the journal Lancet Oncology show that the drug entrectinib is effective and well-tolerated against advanced ...

Zidesamtinib is a novel brain-penetrant ROS1-selective inhibitor created with the aim to overcome limitations observed with currently available ROS1 inhibitors. Zidesamtinib is designed to remain ...

A new study shows that three common laboratory tests used to determine ROS1 status may return false-negative results, meaning that some patients who could benefit from ROS1-directed therapy may be ...

ROS1 fusion genes were successfully detected independent of gender or smoking history in young East Asian patients with lung adenocarcinoma, a histological subgroup in non-small cell lung cancer, ...

An expert explained what ROS1-positive non-small cell lung cancer is and why it is important to identify mutations like ROS1 through genetic sequencing. ROS1-positive non-small cell lung cancer, a ...

An abnormality in the ROS1 gene due to chromosomal rearrangement drove the growth of non–small cell lung cancer tumors, according to study results published in the Journal of Clinical Oncology. The ...

Cancer patients have often organized support and informational groups around their disease types. Now a presentation at the American Association for Cancer Research (AACR) Annual Meeting 2018 ...

Drugs like crizotinib are used to treat patients with ROS1-positive lung cancer. But which patients are ROS1-positive? A University of Colorado Cancer Center study published in the Journal of Thoracic ...

Although ROS1 mutations are quite rare in patients with non-small cell lung cancer (NSCLC), testing for the mutation in all who have the disease is important, as it can play a vital role in ...

(RTTNews) - Nuvalent Inc. (NUVL) announced that its New Drug Application seeking approval of Zidesamtinib for treating adult patients with advanced ROS1-positive non-small cell lung cancer has been ...